E8(R1) GENERAL CONSIDERATIONS FOR CLINICAL STUDIES
Guidance for Industry

Additional copies are available from:
Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10001 New Hampshire Ave., Hillandale Bldg., 4th Floor
Silver Spring, MD 20993-0002
Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353
Email: druginfo@fda.hhs.gov
https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs

and/or

Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 71, Room 3128
Silver Spring, MD 20993-0002
Phone: 800-835-4709 or 240-402-8010
Email: ocod@fda.hhs.gov
https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)

April 2022
ICH

Revision 1
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has the mission of achieving greater regulatory harmonization worldwide to ensure that safe, effective, and high-quality medicines are developed, registered, and maintained in the most resource-efficient manner. By harmonizing the regulatory expectations in regions around the world, ICH guidelines have substantially reduced duplicative clinical studies, prevented unnecessary animal studies, standardized safety reporting and marketing application submissions, and contributed to many other improvements in the quality of global drug development and manufacturing and the products available to patients.

ICH is a consensus-driven process that involves technical experts from regulatory authorities and industry parties in detailed technical and science-based harmonization work that results in the development of ICH guidelines. The commitment to consistent adoption of these consensus-based guidelines by regulators around the globe is critical to realizing the benefits of safe, effective, and high-quality medicines for patients as well as for industry. As a Founding Regulatory Member of ICH, the Food and Drug Administration (FDA) plays a major role in the development of each of the ICH guidelines, which FDA then adopts and issues as guidance to industry.
**TABLE OF CONTENTS**

I. **OBJECTIVES OF THIS DOCUMENT** (1) ................................................................. 1

II. **GENERAL PRINCIPLES** (2) ............................................................................. 2
    A. Protection of Clinical Study Participants (2.1) .................................................... 2
    B. Scientific Approach in Clinical Study Design, Planning, Conduct, Analysis, and Reporting (2.2) .................................................................................................................. 3
    C. Participant Input Into Drug Development (2.3) .................................................... 4

III. **DESIGNING QUALITY INTO CLINICAL STUDIES** (3) ................................ 4
    A. Quality by Design of Clinical Studies (3.1) ......................................................... 4
    B. Critical-to-Quality Factors (3.2) ......................................................................... 5
    C. Approach to Identifying the Critical-to-Quality Factors (3.3) ......................... 6
        1. Establishing a Culture That Supports Open Dialogue (3.3.1) ......................... 6
        2. Focusing on Activities Essential to the Study (3.3.2) ........................................ 7
        3. Engaging Stakeholders in Study Design (3.3.3) ................................................ 7
        4. Reviewing Critical-to-Quality Factors (3.3.4) .................................................. 7
        5. Critical-to-Quality Factors in Operational Practice (3.3.5) ......................... 8

IV. **DRUG DEVELOPMENT PLANNING** (4) ....................................................... 8
    A. Quality of Investigational Medicinal Product (4.1) ............................................ 9
    B. Nonclinical Studies (4.2) .................................................................................. 9
    C. Clinical Studies (4.3) ...................................................................................... 10
        1. Human Pharmacology (4.3.1) ......................................................................... 10
        2. Exploratory and Confirmatory Safety and Efficacy Studies (4.3.2) ...... 11
        3. Special Populations (4.3.3) ............................................................................ 12
        4. Postapproval Studies (4.3.4) ........................................................................ 13
    D. Additional Development (4.4) ......................................................................... 13

V. **DESIGN ELEMENTS AND DATA SOURCES FOR CLINICAL STUDIES** (5) .. 13
    A. Study Population (5.1) .................................................................................... 15
    B. Treatment Description (5.2) ............................................................................ 15
    C. Choice of Control Group (5.3) ......................................................................... 15
    E. Methods To Reduce Bias (5.5) .......................................................................... 17
    F. Statistical Analysis (5.6) ................................................................................ 18
    G. Study Data (5.7) ............................................................................................ 19

VI. **CONDUCT, SAFETY MONITORING, AND REPORTING** (6) ....................... 20
    A. Study Conduct (6.1) ....................................................................................... 20
Contains Nonbinding Recommendations

1. Protocol Adherence (6.1.1) .............................................................. 20
2. Training (6.1.2) ........................................................................... 20
3. Data Management (6.1.3) .......................................................... 21
4. Access to Interim Data (6.1.4) ................................................... 21

B. Participant Safety During Study Conduct (6.2) ....................... 21
   1. Safety Monitoring (6.2.1) .......................................................... 21
   2. Withdrawal Criteria (6.2.2) ...................................................... 22
   3. Data Monitoring Committee (6.2.3) .................................... 22

C. Study Reporting (6.3) .................................................................. 22

VII. CONSIDERATIONS IN IDENTIFYING CRITICAL-TO-QUALITY FACTORS
   (7) .................................................................................................. 23

ANNEX: TYPES OF CLINICAL STUDIES ........................................... 25
This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA office responsible for this guidance as listed on the title page.

This guidance describes internationally accepted principles and practices in the design and conduct of clinical studies of drug and biological products. The guidance is intended to assist sponsors and other parties that design clinical studies, and to promote the quality of the studies submitted to regulatory authorities, while allowing for flexibility. This guidance revises the ICH guidance *E8 General Considerations for Clinical Trials* issued in December 1997. Significant changes from the 1997 version include the following: (1) addresses study quality to ensure the protection of study participants and the generation of reliable and meaningful results, while promoting study efficiency; (2) addresses a broad range of study designs and data sources; and (3) provides updated cross-referencing to other relevant ICH guidances that inform the design, planning, and conduct of clinical research.

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. FDA guidance documents, including this guidance, should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidance means that something is suggested or recommended, but not required.

### I. OBJECTIVES OF THIS DOCUMENT (1)

Clinical studies of medicinal products are conducted to provide information that can ultimately improve access to safe and effective products with meaningful impact on patients, while protecting those participating in the studies. This document provides guidance on the clinical development lifecycle, including designing quality into clinical studies, considering the broad range of clinical study designs and data sources used.

---

1 This guidance was developed within the Expert Working Group (Efficacy) of the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and has been subject to consultation by the regulatory parties, in accordance with the ICH process. This document has been endorsed by the regulatory members of the ICH Assembly at Step 4 of the ICH process, October 2021.

2 The numbers in parentheses reflect the organizational breakdown of the document endorsed by the ICH Assembly at Step 4 of the ICH process, October 2021.
This E8(R1) guidance is intended to:

(1) Describe internationally accepted principles and practices in the design and conduct of clinical studies that will ensure the protection of study participants and facilitate acceptance of data and results by regulatory authorities

(2) Provide guidance on the consideration of quality in the design and conduct of clinical studies across the product lifecycle, including the identification, during study planning, of factors that are critical to the quality of the study, and the management of risks to those factors during study conduct

(3) Provide an overview of the types of clinical studies performed during the product lifecycle, and describe study design elements that support the identification of quality factors critical to ensuring the protection of study participants, the integrity of the data, the reliability of results, and the ability of the studies to meet their objectives

(4) Provide references to the ICH efficacy documents to facilitate the user's access to them

General principles are described in section II (2) of this document, followed by a discussion of designing quality into clinical studies in section III (3). A broad overview of drug development planning and the information provided by different types of studies needed to progress development through the lifecycle of the product is given in section IV (4). In section V (5), important elements of clinical study design are described that reflect the variety of designs used in drug development, as well as the range of data sources available. Section VI (6) addresses study conduct, safety of study participants, and study reporting. Some considerations for identifying factors that are critical to the quality of a study are provided in section VII (7).

The ICH Efficacy Guidelines are an integrated set of guidance covering the planning, design, conduct, safety, analysis, and reporting of clinical studies. ICH E8(R1) provides an overall introduction to clinical development and designing quality into clinical studies and focusing on those factors critical to the quality of the studies. The guidances should be considered and used in an integrated, holistic way rather than focusing on only one guidance or subsection.

For the purposes of this document, a clinical study is meant to refer to a study of one or more medicinal products in humans, conducted at any point in a product’s lifecycle, both prior to and following marketing authorization. The focus is on clinical studies to support regulatory decisions, recognizing these studies may also inform health policy decisions, clinical practice guidelines, or other actions. The term drug should be considered synonymous with therapeutic, preventative, or diagnostic medicinal products. The term drug approval refers to obtaining marketing authorization for the drug.

II. GENERAL PRINCIPLES (2)

A. Protection of Clinical Study Participants (2.1)
Important principles of ethical conduct of clinical studies and the protection of participants, including special populations, have their origins in the Declaration of Helsinki and should be observed in the conduct of all human clinical investigations. These principles are stated in other ICH guidances for industry, in particular, E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) (March 2018). As further described in the ICH E6(R2) guidance, the investigator and sponsor have responsibilities for the protection of study participants together with the Institutional Review Board/Independent Ethics Committee.

The confidentiality of information that could identify participants should be protected in accordance with the applicable regulatory and legal requirement(s).

Before initiating a clinical study, sufficient information should be available to ensure that the drug is acceptably safe for the planned study in humans. Emerging nonclinical, clinical, and pharmaceutical quality data should be reviewed and evaluated, as they become available, by qualified experts to assess the potential implications for the safety of study participants. Ongoing and future studies should be appropriately adjusted, as needed, to take new knowledge into consideration and to protect study participants. Throughout drug development, care should be taken to ensure all study procedures and assessments are necessary from a scientific viewpoint and do not place undue burden on study participants.

B. Scientific Approach in Clinical Study Design, Planning, Conduct, Analysis, and Reporting (2.2)

The essence of clinical research is to ask important questions and answer them with appropriate studies. The primary objectives of any study should reflect the research questions and be clear and explicitly stated. Clinical studies should be designed, planned, conducted, analyzed, and reported according to sound scientific principles to achieve their objectives.

Quality of a clinical study is considered in this document as fitness for purpose. The purpose of a clinical study is to generate reliable information to answer the research questions and support decision-making while protecting study participants. The quality of the information generated should therefore be sufficient to support good decision-making.

Quality by design in clinical research sets out to ensure that the quality of a study is driven proactively by designing quality into the study protocol and processes. This involves the use of a prospective, multidisciplinary approach to promote the quality of protocol and process design in a manner proportionate to the risks involved, and clear communication of how this will be achieved.

Across the product lifecycle, different types of studies will be conducted with different objectives and designs and may involve different data sources. For purposes of this guidance, development planning is considered to cover the entire product lifecycle (section IV (4)). The Annex provides a broad categorization of study type by objective within the different stages of

---

3 Guidances are updated periodically. For the most recent version of a guidance, check the FDA guidance web page at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents.
drug development. Studies should be rigorously designed to address the study objectives with careful attention to the design elements, such as the choice of study population and response variables and the use of methods to minimize biases in the findings (section V (5)).

The cardinal logic behind serially conducted studies is that the results of prior studies should inform the plan of later studies. Emerging data will frequently prompt a modification of the development strategy. For example, results of a confirmatory study may suggest a need for additional human pharmacology studies.

The availability of multi-regional data as a result of the increased globalization of drug development programs, facilitated by the harmonization of ICH guidances, minimizes the need to conduct individual studies in different regions. The results of a study are often used in regulatory submissions in multiple regions, and the design should also consider the relevance of the study results for regions other than the one(s) in which the study is conducted. Further guidance is provided by the ICH guidances for industry E5 Ethnic Factors in the Acceptability of Foreign Clinical Data (June 1998), E6(R2), and E17 General Principles for Planning and Design of Multiregional Clinical Trials (July 2018).

Early engagement with regulatory authorities to understand local/regional requirements and expectations is encouraged and will facilitate the ability to design quality into the study.

C. Patient Input into Drug Development (2.3)

Consulting with patients and/or patient organizations during drug development can help to ensure that patients’ perspectives are captured. The views of patients (or of their caregivers/parents) can be valuable throughout all phases of drug development. Involving patients early in the design of a study is likely to increase trust in the study, facilitate recruitment, and promote adherence. Patients also provide their perspective of living with a condition, which may contribute to the determination, for example, of endpoints that are meaningful to patients, selection of the appropriate population and duration of the study and use of acceptable comparators. This ultimately supports the development of drugs that are better tailored to patients’ needs.

III. DESIGNING QUALITY INTO CLINICAL STUDIES (3)

The quality by design approach to clinical research (section III.A (3.1)) involves focusing on critical-to-quality factors to ensure the protection of the rights, safety, and well-being of study participants; the generation of reliable and meaningful results; and the management of risks to those factors using a risk proportionate approach (section III.B (3.2)). The approach is supported by the establishment of an appropriate framework for the identification and review of critical-to-quality factors (section III.C (3.3)) at the time of design and planning of the study, and throughout its conduct, analysis, and reporting.

A. Quality by Design of Clinical Studies (3.1)
Quality is a primary consideration in the design, planning, conduct, analysis, and reporting of clinical studies and a necessary component of clinical development programs. The likelihood that a clinical study will answer the research questions while preventing important errors can be dramatically improved through prospective attention to the design of all components of the study protocol, procedures, associated operational plans and training. Activities such as document and data review and monitoring, where conducted retrospectively, are an important part of a quality assurance process; but even when combined with audits, they are not sufficient to ensure the quality of a clinical study.

Good planning and implementation of a clinical study also derive from attention to the design elements of clinical studies as described in section V (5), such as:

- The need for clear, predefined study objectives that address the primary scientific question(s)
- Selection of appropriate participants that have the disease, condition, or molecular/genetic profile that is being studied
- Use of approaches to minimize bias, such as randomization, blinding or masking, and/or control of confounding
- Endpoints that are well defined, measurable, clinically meaningful, and relevant to patients

Operational criteria are also important, such as ensuring a clear understanding of the feasibility of the study, selection of suitable investigator sites, quality of specialized analytical and testing facilities and procedures, and processes that ensure data integrity.

B. Critical-to-Quality Factors (3.2)

A basic set of factors relevant to ensuring study quality should be identified for each study. Emphasis should be given to those factors that stand out as critical to study quality. These critical-to-quality factors are attributes of a study whose integrity is fundamental to the protection of study participants, the reliability and interpretability of the study results, and the decisions made based on the study results. These quality factors are considered to be critical because, if their integrity were to be undermined by errors of design or conduct, the reliability or ethics of decision-making based on the results of the study would also be undermined. Critical-to-quality factors should also be considered holistically, so that dependencies among them can be identified. Section VII (7) of this document provides considerations that can help identify critical-to-quality factors for a study.

The design of a clinical study should reflect the state of knowledge and experience with the drug; the condition to be treated, diagnosed, or prevented; the underlying biological mechanism (of both the condition and the treatment); and the population for which the drug is intended. As research progresses, knowledge increases and uncertainties about the pharmacology, safety, and
efficacy of a drug decreases. Knowledge of the drug at any point in development will continually inform the identification of critical-to-quality factors and control processes used to manage them.

The sponsor and other parties designing quality into a clinical study should identify the critical-to-quality factors. Having identified those factors, it is important to determine the risks that threaten their integrity and decide whether they can be accepted or should be mitigated, based on their probability, detectability and impact. Where it is decided that risks should be mitigated, the necessary control processes should be put in place and communicated, and the necessary actions taken to mitigate the risks. The term risk is used here in the context of general risk management methodology applicable to all factors of a study.

Proactive communication of the critical-to-quality factors and risk mitigation activities will support understanding of priorities and resource allocation by the sponsor and investigator sites. Proactive support (e.g., training to site staff, relevant to their role, and description of critical-to-quality factors and potential mitigation measures in the protocol) will enhance correct implementation of study protocol, procedures, and associated operational plans and process design.

Perfection in every aspect of an activity is rarely achievable or can only be achieved by use of resources that are out of proportion to the benefit obtained. The quality factors should be prioritized to identify those that are critical to the study, at the time of the study design, and study procedures should be proportionate to the risks inherent in the study and the importance of the information collected. The critical-to-quality factors should be clear and should not be cluttered with minor issues (e.g., due to extensive secondary objectives or processes/data collection not linked to the proper protection of the study participants and/or primary study objectives).

C. Approach to Identifying the Critical-to-Quality Factors (3.3)

A key aspect of a quality approach to study design is to ask whether the objectives being addressed by the study are clearly articulated; whether the study is designed to meet the research questions it sets out to address; whether these questions are meaningful to patients; and whether the study hypotheses are specific and scientifically valid. The approach to the identification of the critical-to-quality factors should consider whether those objectives can be met, well and most efficiently, by the chosen design and data sources. Patient consultation early in the study design process can contribute to this approach and ultimately help to identify the critical-to-quality factors. Study designs should be operationally feasible and avoid unnecessary complexity. Protocols and case report forms/data collection methods should enable the study to be conducted as designed and avoid unnecessary data collection.

Identification of critical-to-quality factors will be enhanced by approaches that include the following elements:

1. Establishing a Culture That Supports Open Dialogue (3.3.1)

Creating a culture that values and rewards critical thinking and open, proactive dialogue about what is critical-to-quality for a particular study or development program, going beyond sole
reliance on tools and checklists, is encouraged. Open dialogue can facilitate the development of innovative methods for ensuring quality.

Inflexible, one size fits all approaches should be discouraged. Standardized operating procedures are necessary and beneficial for conducting good quality clinical studies, but study-specific strategies and actions are also needed to effectively and efficiently support quality in a study.

Evidence used to inform the study design should be gathered and reviewed, before and during the study, in a transparent manner, while acknowledging gaps in data and conflicting data, where present and known, and anticipating the possible emergence of such gaps or conflicts.

2. **Focusing on Activities Essential to the Study (3.3.2)**

Efforts should be focused on activities that are essential to the reliability and meaningfulness of study outcomes for patients and public health, and the safe, ethical conduct of the study for participants. Consideration should be given to eliminating nonessential activities and data collection from the study to increase quality by simplifying conduct, improving study efficiency, and targeting resources to critical areas. Resources should be deployed to identify and prevent or control errors that matter.

3. **Engaging Stakeholders in Study Design (3.3.3)**

Clinical study design is best informed by input from a broad range of stakeholders, including patients and health care providers. It should be open to challenge by subject matter experts and stakeholders from outside, as well as within, the sponsor organization.

The process of building quality into the study may be informed by participation of those directly involved in successful completion of the study such as clinical investigators, study coordinators and other site staff, and patients/patient organizations. Clinical investigators and potential study participants have valuable insights into the feasibility of enrolling participants who meet proposed eligibility criteria, whether scheduled study visits and procedures may be overly burdensome and lead to early dropouts, and the general relevance of study endpoints and study settings to the targeted patient population. They may also provide insight into the value of a treatment in the context of ethical issues, culture, region, demographics, and other characteristics of subgroups within a targeted patient population.

Early engagement with regulatory authorities is encouraged, particularly when a study has novel elements considered critical-to-quality (e.g., defining patient populations, procedures, or endpoints).

4. **Reviewing Critical-to-Quality Factors (3.3.4)**

Accumulated experience and knowledge, together with periodic review of critical-to-quality factors should be used to determine whether adjustments to risk control mechanisms are needed, because new or unanticipated issues may arise once the study has begun.
Contains Nonbinding Recommendations

Studies with adaptive features and/or interim decision points should be given specific attention during proactive planning and ongoing review of critical-to-quality factors, and risk management (ICH guidance for industry E9 Statistical Principles for Clinical Trials (September 1998)).

5. Critical-to-Quality Factors in Operational Practice (3.3.5)

The foundation of a successful study is a protocol that is both scientifically sound and operationally feasible. A feasibility assessment involves consideration of study design and implementation elements that could impact the successful completion of clinical development from an operational perspective.

Feasibility considerations also include, but are not limited to, regional differences in medical practice and patient populations, the availability of qualified investigators/site personnel with experience in conducting a clinical study (ICH E6(R2)), availability of equipment and facilities required to successfully conduct the study, availability of the targeted patient population, and ability to enroll a sufficient number of participants to meet the study objectives. The retention and follow-up of study participants are also key critical-to-quality factors. Consideration of these and other critical-to-quality factors relating to study feasibility can inform study design and enhance quality implementation.

IV. DRUG DEVELOPMENT PLANNING (4)

This section provides general principles to consider in drug development planning. Drug development planning should adhere to the principles of scientific research and good study design that ensure the reliability and interpretability of results. Efficient drug development includes appropriately planned interactions with regulatory authorities throughout development to ensure alignment with requirements for product quality and to support approval in the condition or disease, including possible post-approval studies to address remaining questions. Throughout this process there is critical attention to the protection of the rights, safety, and well-being of study participants.

Drug development planning builds on knowledge acquired throughout the investigational process to reduce levels of uncertainty as the process moves from target identification through nonclinical and clinical evaluation. Such planning encompasses quality of medicinal product, including chemistry, manufacturing, and controls, and nonclinical and clinical studies (pre- and post-approval). Modelling and simulation may inform drug development throughout the process. Planning may also include regional considerations for product introduction into the market, such as health technology assessments.

It is important to ensure that the experiences, perspectives, needs, and priorities of relevant stakeholders relating to the development and evaluation of the drug throughout its lifecycle are captured and meaningfully incorporated into drug development planning.

Clinical development may also feature requirements for co-development of validated biomarkers, diagnostic testing, or devices that facilitate the safe and effective use of a drug.
The types of studies that can contribute to drug development are described in subsections IV.B (4.2) and IV.C (4.3) and summarized in the Annex.

A. Quality of Investigational Medicinal Product (4.1)

Ensuring adequate quality and characterization of physicochemical properties of investigational medicinal product is an important element in planning a drug development program and is addressed in ICH and regional quality guidances. More extensive characterization may be required for complex or biological products. Formulations should be well characterized in the drug development plan, including information on bioavailability, wherever feasible, and should be appropriate for the stage of drug development and the targeted patient population. Age-appropriate formulation development may be a consideration when clinical studies are planned in pediatric populations (ICH guidances for industry E11 Clinical Investigation of Medicinal Products in the Pediatric Population (December 2000) and E11(R1) Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population (April 2018)).

Evaluation of the quality of a drug may extend to devices required for its administration or a companion diagnostic to identify the targeted population.

Changes in a product during development should be supported by comparability data to ensure the ability to interpret study results across the development program. This includes establishing links between formulations through bioequivalence studies or other means.

B. Nonclinical Studies (4.2)

Guidance on nonclinical safety studies is provided in the ICH guidance for industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (January 2010), in ICH Safety (S) Guidances and related question-and-answer documents, as well as in regional guidance. The nonclinical assessment usually includes toxicology, carcinogenicity, immunogenicity, pharmacology, pharmacokinetics, and other evaluations to support clinical studies (and may encompass evidence generated in in vivo and in vitro models, and by modelling and simulation). The scope of nonclinical studies, and their timing with respect to clinical studies, depend on a variety of factors that inform further development, such as the drug’s chemical or molecular properties; pharmacological basis of principal effects (mechanism of action); route(s) of administration; absorption, distribution, metabolism, and excretion; physiological effects on organ systems; dose/concentration-response relationships; metabolites; and duration of action and use. Use of the drug in special populations (e.g., pregnant or breast-feeding people, children) may require additional nonclinical assessments. Guidance for nonclinical safety studies to support human clinical studies in special populations should be reviewed (see, e.g., the ICH guidances for industry S5(R3) Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals (May 2021), S11 Nonclinical Safety Testing in Support of Development of Pediatric Pharmaceuticals (May 2021), and M3(R2).

Assessment of the preclinical characteristics, including physiological and toxicological effects of the drug, serves to inform clinical study design and planned use in humans. Before proceeding to
Contains Nonbinding Recommendations

studies in humans, there should be sufficient nonclinical information to support initial human doses and duration of exposure.

C. Clinical Studies (4.3)

Clinical drug development, defined as studying the drug in humans, is conducted in a sequence that builds on knowledge accumulated from nonclinical and previous clinical studies. The structure of the drug development program is shaped by many considerations and comprised of studies with different objectives, designs, and dependencies. The Annex provides an illustrative list of example studies and their objectives. Although clinical drug development is often described as consisting of four temporal phases (phases 1 through 4), it is important to appreciate that the phase concept is a description and not a requirement, and that the phases of drug development may overlap or be combined.

To develop new drugs efficiently, it is essential to identify their characteristics in the early stages of development and to plan an appropriate development program based on this profile. Initial clinical studies may be more limited in size and duration to provide an early evaluation of short-term safety and tolerability, as well as proof of concept of efficacy. These studies may provide pharmacodynamics, pharmacokinetics, and other information needed to choose a suitable dosage range and/or administration schedule to inform further clinical studies. As more information is known about the drug, clinical studies may expand in size and duration, may include more diverse study populations, and may include more secondary endpoints in addition to the primary measures of efficacy. Throughout development, new data may suggest the need for additional studies.

The use of biomarkers has the potential to facilitate the availability of safer and more effective drugs, to guide dose selection, and to enhance a drug’s benefit-risk profile (see the ICH guidance for industry E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions (August 2011)) and can be considered throughout drug development. Clinical studies may evaluate the use of biomarkers to better target patients more likely to benefit and less likely to experience adverse reactions, or as intermediate endpoints that could predict clinical response.

The following subsections describe the types of studies that typically span clinical development from the first studies in humans through late development and post-approval.

1. Human Pharmacology (4.3.1)

The protection of study participants should always be the first priority when designing early clinical studies, especially for the initial administration of an investigational product to humans (usually referred to as phase 1). These studies may be conducted in healthy volunteer participants or in a selected population of patients who have the condition or the disease, depending on drug properties and the objectives of the development program.

These studies typically address one or a combination of the following aspects:
a. Estimation of Initial Safety and Tolerability (4.3.1.1)

The initial and subsequent administration of a drug to humans is usually intended to determine the tolerability of the dose range expected to be evaluated in later clinical studies and to determine the nature of adverse reactions that can be expected. These studies typically include both single- and multiple-dose administration.

b. Pharmacokinetics (4.3.1.2)

Characterization of a drug's absorption, distribution, metabolism, and excretion continues throughout the development program, but the preliminary characterization is an essential early goal. Pharmacokinetic (PK) studies are particularly important to assess the clearance of the drug and to anticipate possible accumulation of parent drug or metabolites, interactions with metabolic enzymes and transporters, and potential drug-drug interactions. Some PK studies are commonly conducted in later phases to answer more specialized questions. For orally administered drugs, the study of food effects on bioavailability is important to inform the dosing instructions in relation to food. Obtaining PK information in subpopulations with potentially different metabolism or excretion, such as patients with renal or hepatic impairment, geriatric patients, children, and ethnic subgroups, should be considered (ICH guidances for industry E4 Dose-Response Information to Support Drug Registration (November 1994), E7 Studies in Support of Special Populations: Geriatrics (August 1994), E11 and E11(R1) Addendum, and E5, respectively).

c. Pharmacodynamics and Early Measurement of Drug Activity (4.3.1.3)

Depending on the drug and the endpoint of interest, pharmacodynamic (PD) studies and studies relating drug levels to response (PK/PD studies) may be conducted in healthy volunteer participants or in patients with the condition or disease. If there is an appropriate measure, PD data can provide early estimates of activity and efficacy and may guide the dosage and dose regimen in later studies.

2. Exploratory and Confirmatory Safety and Efficacy Studies (4.3.2)

After initial clinical studies provide sufficient information on safety, clinical pharmacology, and dose, exploratory and confirmatory studies (usually referred to as phases 2 and 3, respectively) are conducted to further evaluate both the safety and efficacy of the drug. Depending on the nature of the drug and the patient population, this objective may be combined in a single or small number of studies. Exploratory and confirmatory studies may use a variety of study designs depending on the objective of the study.

Exploratory studies are designed to investigate safety and efficacy in a selected population of patients for whom the drug is intended. Additionally, these studies aim to refine the effective dose(s) and regimen, refine the definition of the targeted population, provide a more robust safety profile for the drug, and include evaluation of potential study endpoints for subsequent studies. Exploratory studies may provide information on the identification and determination of
factors that affect the treatment effect and possibly combined with modelling and simulation, serve to support the design of later confirmatory studies.

Confirmatory studies are designed to confirm the preliminary evidence accumulated in earlier clinical studies that a drug is safe and effective for use for the intended indication and recipient population. These studies are often intended to provide an adequate basis for marketing approval, and to support adequate instructions for use of the drug and official product information. They aim to evaluate the drug in participants with or at risk of the condition or disease who represent those who will receive the drug once approved. This may include investigating subgroups of patients with frequently occurring or potentially relevant co-morbidities (e.g., cardiovascular disease, diabetes, hepatic and renal impairment) to characterize the safe and effective use of the drug in patients with these conditions.

Confirmatory studies may evaluate the efficacy and safety of more than one dose or the use of the drug in different stages of disease or in combination with one or more other drugs. If the intent is to administer a drug for a long period of time, then studies involving extended exposure to the drug should be conducted using the ICH guidance for industry E1A The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions (March 1995). Irrespective of the intended duration of administration, the duration of effect of the drug will also inform the duration of follow-up.

Study endpoints selected for confirmatory studies should be clinically relevant and reflect disease burden or be of adequate surrogacy for predicting disease burden or sequelae.

3. Special Populations (4.3.3)

Some groups in the general population may need additional investigation during drug development because they have unique risk/benefit considerations, or because they can be anticipated to need modification of the dose or schedule of a drug. ICH E5 and E17 provide a framework for evaluating the impact of ethnic factors on a drug’s effect. Particular attention should be paid to the ethical considerations related to informed consent in vulnerable populations (ICH E6(R2) and E11). Studies in special populations may be conducted during any phase of development to understand the drug effects in these populations. Some considerations of special populations are the following:

a. Investigations in Pregnant People (4.3.3.1)

Investigation of drugs that may be used in pregnancy is important. Where pregnant people volunteer to be enrolled in a clinical study, or a participant becomes pregnant while participating in a clinical study, follow-up evaluation of the pregnancy and its outcome and the reporting of outcomes should be done.

b. Investigations in Lactating People (4.3.3.2)
Excretion of the drug or its metabolites into human milk should be examined where applicable and feasible. When nursing people are enrolled in clinical studies, their babies are usually also monitored for the effects of the drug.

c. Investigations in Children (4.3.3.3)

ICH E11 and E11(R1) Addendum provide an outline of critical issues in pediatric drug development and approaches to the safe, efficient, and ethical study of drugs in pediatric populations.

d. Investigations in Geriatric Populations (4.3.3.4)

ICH E7 provides an outline of critical issues in developing drugs for use in geriatric populations and approaches to their safe, efficient, and ethical study.

4. Post-Approval Studies (4.3.4)

After the approval of a drug, additional studies may be conducted to further understand the safety and efficacy of the drug in its approved indication (usually referred to as phase 4). These are studies that were not considered necessary for approval but are often important for optimizing the drug's use. They may be of any type but should have valid scientific objectives. Post-approval studies may be conducted to address a regulatory requirement.

Postapproval studies may be performed to provide additional information on the efficacy, safety, and use of the drug in populations more diverse than included in the studies conducted prior to marketing authorization. Studies with long-term follow-up or with comparisons to other treatment options or standards of care may provide important information on safety and efficacy. Commonly conducted studies include additional drug-drug interaction, dose-response or safety studies, and studies designed to support use under the approved indication (e.g., mortality/morbidity studies, epidemiological studies). These studies may explore use of the drug in the real-world setting of clinical practice and may also inform health economics and health technology assessments.

D. Additional Development (4.4)

After initial approval, drug development may continue with studies of new or modified indications in new patient populations, new dosage regimens, or new routes of administration. If a new dose, formulation, or combination is studied, additional nonclinical and/or human pharmacology studies may be indicated. Data from previous studies or from clinical experience with the approved drug may inform these programs.

V. DESIGN ELEMENTS AND DATA SOURCES FOR CLINICAL STUDIES (5)

Study objectives impact the choice of study design and data sources, which in turn impact the strength of a study to support regulatory decisions and clinical practice. As discussed in section
IV (4), there are a wide variety of study objectives in drug development. Similarly, there is a wide range of study designs and data sources to address these objectives. Sections V.A (5.1) through V.F (5.6) discuss key elements that can be used to define the study design, and section V.G (5.7) discusses the various data sources that can be used for the study.

Clear objectives will help to specify the study design, and conversely, the process of specifying the design may help to further clarify the objectives. At the design stage, the objectives may need to be modified if substantial practical considerations and limitations or other risks to critical-to-quality factors are identified. The study objectives are further refined through specification of estimands. Estimands, discussed in the ICH guidance for industry E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials (May 2021), provide a precise description of the treatment effects reflecting the clinical questions posed by the study objectives. The estimand summarizes at a population level what the outcomes would be in the same patients under the different treatment conditions being compared.

An important distinction between studies is whether the allocation of individuals to the study drug(s) is controlled by the study procedures, or allocation to the drug is not controlled but exposure to the drug(s) is observed in the study. In this document, the former case is referred to as an interventional study and the latter case is referred to as an observational study.

Interventional studies, and in particular randomized studies, play a central role in drug development, because they can better control biases. The designs of randomized studies range from simple parallel group designs to more complex variants. For example, adaptive design studies allow prospectively planned modifications to the study, such as changes in the population studied or changes in doses of the drug studied over the course of the study, based on accumulating data. Master protocol studies allow for the investigation of multiple drugs or multiple conditions under a shared framework. Platform studies allow for multiple drugs to be investigated in a continuous manner, with different drugs entering the study at different times and leaving the study based on prespecified decision rules.

Studies without randomization (whether interventional or observational) can play a role as well in certain settings when randomization is not feasible. Observational studies are often conducted post-approval but can be of utility as complementary sources of evidence during development and across the lifecycle of a drug.

Along with the breadth of study designs, there are multiple sources of data that studies may employ. Traditionally, studies have used study-specific data collection processes. Data such as that obtained from electronic medical records or digital health technologies may be leveraged to increase the efficiency of studies or generalizability of study results.

This section presents important elements that define the design of a clinical study, including population, treatment, control group, response variable, methods to reduce bias, statistical analysis, and data sources. It is intended to assist in identifying the critical-to-quality factors necessary to achieve the study objectives, while also enabling flexibility in study design and promoting efficiency in study conduct. Although the focus is on interventional studies, the discussion is intended to apply to both interventional and observational studies. The elements
outlined here are expected to be relevant to study types and data sources that are used in clinical studies now and that may be developed in the future.

A. Study Population (5.1)

The population to be studied should be chosen to support the study objectives and is defined through the inclusion and exclusion criteria for the study. The degree to which a study succeeds in enrolling the desired population will impact the ability of the study to meet its objectives.

The study population may be narrowly defined to reduce the risk to study participants or to maximize the sensitivity of the study for detecting a certain effect. Conversely, it may be broadly defined to more closely represent the diverse populations for which the drug is intended. In general, studies conducted early in a development program, when little is known about the safety of the drug, are more homogeneous in study population definitions. Studies conducted in the later phases of drug development or post-approval are often more heterogeneous in study population definitions. Such studies should involve participants who are representative of the diverse populations that will receive the intervention in clinical practice. Available knowledge about participant characteristics that may predict disease outcomes or effects of the intervention can be used to further define the study population.

The number of participants (sample size) in a study should be large enough to provide a reliable answer to the questions addressed (see ICH E9). This number is usually determined by the primary objective of the study. If the sample size is determined on some other basis, then this should be made clear and justified. For example, a sample size determined to address safety questions or meet important secondary objectives may need larger numbers of participants than needed for addressing the primary efficacy question (see ICH E1A). If study objectives include obtaining information on certain subgroups, then efforts should be made to ensure adequate representation of these subgroups.

B. Treatment Description (5.2)

The treatment(s), including controls, under study should be described explicitly and specifically. These might be individual treatments (including different doses or regimens), combinations of treatments, or no treatments, and can include specification of background treatments. The definition of treatments should align with the objectives of the study (ICH E9(R1)). For example, if the objective of the study is to understand the effect of the treatment in clinical practice, the study may specify that the background treatment, if any, is up to the discretion of the participants and health care providers. If the objectives are to understand the effect of the drug when added to a specific background treatment, the background treatment should be defined explicitly and specifically for all groups including controls.

C. Choice of Control Group (5.3)

The major purpose of a control group is to separate the effect of the treatment(s) from the effects of other factors such as natural course of the disease, other medical care received, or observer or patient expectations (ICH guidance for industry E10 Choice of Control Group and Related...
Issues in Clinical Trials (May 2001)). The treatment effect of interest may be the effect relative to not receiving the drug or the effect relative to receiving other therapies. Comparisons may be made with placebo, no treatment, standard of care, other treatments, or different doses of the drug under investigation.

The source of control group data may be internal or external to the study. The intent of using an internal control group is to help ensure that the only differences between treatment groups are due to the treatment they receive and not due to differences in the selection of participants, the timing and measurement of study outcomes, or other differences. A special case of an internal control group is when each participant serves as their own internal control by receiving the drug and control at different points of time. With use of an external control group, individuals are selected from an external source, and the individuals may have been treated at an earlier time (historical control group) or during the same time but in another setting than participants in the study.

Important limitations of the use of external controls are discussed in ICH E10. Particular care is needed to minimize the likelihood of erroneous inference. The use of an external control requires that the disease course is well known and predictable. External control individuals may differ from study participants with respect to demographic and background characteristics (e.g., medical history, concurrent diseases). In addition, external control individuals may differ from participants in the study with respect to concurrent care and the measurement of study outcomes and other data elements. Because the use of internal controls generally mitigates the potential for bias better than external controls, particularly in conjunction with randomization, the suitability of the use and choice of external control should be carefully considered and justified. Section V.E (5.5) discusses the sources of bias that can arise in observational studies and is relevant to the use of external controls.

Participant level data may not be available for some choices of external control groups. Summary measures may be available to form the basis of comparisons with treated participants to estimate drug effects and test hypotheses about those effects. There is, however, less ability to control for differences in characteristics between study individuals in the external control group and study participants in the internal treatment groups in making these comparisons or examining the quality and completeness of individual data elements. Additionally, there may not be the ability to examine subgroups or modify the response variable to be consistent with the response variable used in the study.

**D. Response Variables (5.4)**

A response variable is an attribute of interest that may be affected by the drug. The response variable may relate to pharmacokinetics, pharmacodynamics, efficacy or safety of the drug, or to the use of the drug, including, for example, in adherence to risk minimization measures post-approval. Study endpoints are the response variables that are chosen to assess drug effects.

The primary endpoint should be capable of providing clinically relevant and convincing evidence related to the primary objective of the study (ICH E9). Secondary endpoints are either supportive
measurements related to the primary objective or measurements of effects related to the secondary objectives. Exploratory endpoints are used to further explain or to support study findings or to explore new hypotheses for later research. The choice of endpoints should be meaningful for the intended population and may also take into account the views of patients. The definition of each study endpoint should be specific and include how and at what time points in a participant’s treatment course of the drug and follow-up it is ascertained.

Knowledge of the drug, along with the clinical context and purpose of a given study, affect what response variables should be collected. For example, a proof-of-concept study of relatively short duration could employ a pharmacodynamic outcome rather than the outcome of primary interest. A larger study of longer duration could then be used to confirm a clinically meaningful effect on the outcome of primary interest. In other cases, such as a study where the safety profile of the drug is well characterized, the extent of safety data collection can be tailored to the objectives of the study.

E. Methods to Reduce Bias (5.5)

The study design should address potential sources of bias that can undermine the reliability of results. Although different types of studies are subject to different sources of bias, this section addresses some common sources. ICH E9 discusses principles for controlling and reducing bias mainly in the context of interventional studies.

In studies with internal control groups, randomization is used to ensure comparability of treatment groups, thereby minimizing the possibility of bias in treatment assignment.

Randomization at the start of the study addresses differences between the groups at the time of randomization but does not prevent bias because of differences arising during the study. Events after randomization (particularly intercurrent events (ICH E9(R1)) may affect the validity and interpretation of comparisons between treatment groups. Examples include treatment discontinuation or use of rescue medications. There may also be differences in the follow-up patterns between the groups due to participants in one group discontinuing the study at different rates, because of, for example, adverse events or perceived lack of efficacy. Careful consideration of the potential for intercurrent events to occur during the study and their impact will help with the identification of critical-to-quality factors, such as reducing study discontinuation, continuing data collection following treatment discontinuation, and retrieving data after study discontinuation, if appropriate. It is important when defining the treatment effect (estimand) to account for the occurrence of intercurrent events.

Concealing the treatment assignments (blinding) limits the occurrence of conscious or unconscious bias in the conduct and interpretation of a clinical study that may affect the course of treatment, monitoring, endpoint ascertainment, and participants’ responses. In a single-blind study, the investigator is aware of the treatment but the participant is not. When the investigators who are involved in the treatment or clinical evaluation of the participants are also unaware of the treatment assignments, the study is referred to as double-blind. In an open-label study, the consequences of the lack of blinding may be reduced through the use of prespecified decision rules for aspects of study conduct, such as recruitment, treatment assignment, participant
management, safety reporting, and response variable ascertainment. Blinding for staff at the study sites or sponsor should be implemented where feasible.

Knowledge of interim results (whether individual or treatment group level) has the potential to introduce bias or influence the conduct of the study and interpretation of study results. Specific considerations related to information flow and confidentiality are therefore important.

Observational studies introduce unique challenges to the assessment and control of bias. These include ensuring that the individuals have the condition under study and ensuring comparability between treatment groups in prognostic factors associated with the choice of therapies, in the ascertainment of response variables, and in post-baseline concomitant patient care. These challenges may also exist with the use of external controls in an interventional study. Methods exist that may mitigate some of these challenges and should be considered during the design phase.

**F. Statistical Analysis (5.6)**

The statistical analysis of a study encompasses important elements necessary to achieving the study objectives. The specification and documentation of the statistical analysis are important for ensuring the integrity of the study findings. The principal features of the statistical analysis should be planned during the design of the study and should be clearly specified in a protocol written before the study begins (ICH E9). Full details of the planned statistical analysis should be specified and documented before knowledge of the study results that may reveal the drug effects, which may be accomplished using a separate statistical analysis plan. The protocol should define the estimand(s) following the framework established in ICH E9(R1).

Statistical analyses of primary and secondary endpoints that address key study objectives with respect to both efficacy and safety should be described in the protocol, including any interim analyses and/or planned design adaptations. Other statistical aspects of the study that should be described in the protocol include the analytical methods for any planned estimation and tests of hypotheses about the drug effect and a justification of the sample size.

The statistical analysis should include prespecified sensitivity analyses for assessing the impact of the assumptions made for the primary and important secondary analyses on the results of the study (ICH E9(R1)). For example, if the analysis relies on a particular assumption about the reasons for missing data, sensitivity analyses should be planned to assess the impact of that assumption on the study results. In the case of observational studies, sensitivity analyses might, for example, consider additional potential confounders.

For double-blind studies, the statistical analysis plan should be finalized before treatment assignments are revealed. Therefore, if a study includes one or more interim analyses, the planned statistical analysis should not be changed after an interim analysis that involves unblinding. For open-label and single-blind studies, details pertaining to the primary and important secondary analyses would ideally be finalized before the first participant is randomized or allocated to study intervention.
Prespecification of the analysis approach is particularly important for studies that use existing data sources rather than primary data collection (section V.G (5.7)), not only for the statistical analysis planned for the study but also for any feasibility analysis to assess the applicability of the existing data. For example, for a single-arm interventional study with an external control, the specifics of the external control should be defined before conducting the interventional aspect of the study. Prespecification of the analysis should be in place so that any review of the existing data sources before the design of the study does not threaten the study integrity.

The statistical analysis should be carried out in accordance with the prospectively defined analysis plan, and all deviations from the plan should be indicated in the study report (ICH guidance for industry *E3 Structure and Content of Clinical Reports* (July 1996)).

**G. Study Data (5.7)**

Study data comprise all information generated, collected, or used in the context of the study, ranging from existing source data to study-specific assessments. The study data should contain the necessary information to conduct the statistical analysis specified in the protocol and statistical analysis plan, as well as to monitor for participant safety, protocol adherence, and data integrity.

Study data can be broadly classified into two types: (1) data generated specifically for the present study (primary data collection); and (2) data obtained from sources external to the present study (secondary data use). Data generated for the study may be collected via case report forms, laboratory measurements, electronic patient-reported outcomes, or mobile health tools. Examples of external sources of data include historical clinical studies, national death databases, disease and drug registries, claims data, and medical and administrative records from routine medical practice. A study may make use of both types of data.

For all data sources, procedures to ensure the protection of personal data of the individuals being studied should be implemented. The study protocol, and if applicable the informed consent, should explicitly address the protection of personal data. Regulations related to protection of individuals’ data need to be followed. When considering data from external sources, it is important to ascertain whether the regulatory authorities accept the use of such data for purposes other than the original intent.

Study data should be of sufficient quality to address the objectives of the study and, in interventional studies, to monitor participant safety. Data quality attributes include consistency (uniformity of ascertainment over time); accuracy (correctness of collection, transmission, and processing); and completeness (lack of missing information). These aspects should be proactively considered during study planning by identifying the factors, critical to the quality of the study, associated with data sourcing, collection, and processing.

The use of standards for data recording and coding (or recoding) is important to support data reliability, facilitate correct analysis and interpretation of results, and promote data sharing. Internationally accepted data standards exist for many sources of study data and should be used where applicable.
With primary data collection, the methods and standards established for use at the point of capture and the subsequent processing provide an opportunity to prospectively ensure the quality of the data.

With secondary data use, the relevance of the available data should be considered and clearly described in the study protocol. For example, when using existing electronic health record data to ascertain the study endpoint rather than through primary data collection, information in the health record about outcomes may need to be converted to the study endpoint.

In some cases, secondary data use may not be sufficient for all aspects of the study and may need to be supplemented by primary data collection. The quality of data collected for a different purpose should be evaluated when reused in the context of the present study. Careful quality control processes may have been applied during their acquisition; where used, those processes were not necessarily designed with the objectives of the present study in mind.

There are several additional considerations with secondary data use. For example, methods to conceal the treatment should be considered when selecting, and prior to analyzing, data from external sources. As another example, absence of affirmative information on a condition or event does not necessarily mean the condition or event is not present. There may also be a delay between the occurrence of events and their appearance in existing data sources. To the extent possible, uncertainties and potential sources of bias should be addressed at the study design stage, during data analysis, and in the interpretation of the study results.

VI. CONDUCT, SAFETY MONITORING, AND REPORTING (6)

A. Study Conduct (6.1)

The principles and approaches set out in this guidance, including those of quality by design, should inform the approach taken to the conduct and reporting of clinical studies. Risk proportionate mitigation measures should be employed to ensure the integrity of the critical-to-quality factors.

1. Protocol Adherence (6.1.1)

Adherence to the study protocol and other relevant documents is important, and many aspects of adherence should be considered among the study’s critical-to-quality factors. Successful application of the quality by design principles may minimize the need for modifications to the protocol and make adherence throughout the study more likely. If modification of the protocol becomes necessary, a clear description of the rationale for the modification should be provided in a protocol amendment, and the impact of the modification on study conduct should be carefully considered.

2. Training (6.1.2)
Individuals involved in study conduct should receive training commensurate with their role in the study, and this training should occur prior to their becoming involved in the study. Updated training or retraining may be needed to address issues related to critical-to-quality factors observed during the course of the study, and/or to implement protocol modifications.

3. **Data Management (6.1.3)**

The manner and timelines in which study data are collected and managed are critical contributors to overall study data quality. Operational checks, centralized data monitoring, and statistical surveillance can identify important data quality issues for corrective action. Data management procedures should account for the diversity of data sources in use for clinical studies (section V.G (5.7)). For interventional clinical studies, further guidance on data management is available in ICH E6(R2).

4. **Access to Interim Data (6.1.4)**

Inappropriate access to data during the conduct of the study may compromise study integrity (sections V.E (5.5) and V.F (5.6) and ICH E9). In studies with planned interim analyses, special attention should be given to which individuals have access to the data and results. Even in studies without planned interim analyses, special attention should be paid to any ongoing monitoring of unblinded data to avoid inappropriate access.

B. **Participant Safety During Study Conduct (6.2)**

Important standards of ethical conduct and the protection of participants in clinical studies are described in section II.A (2.1). This section describes safety-related considerations during the conduct of the study.

1. **Safety Monitoring (6.2.1)**

The goals of safety monitoring are to protect study participants and to characterize the safety profile of the drug. Procedures and systems for the identification, monitoring, and reporting of safety concerns during the study should be clearly specified. The approach should reflect the type and objectives of the study, the risks to the study participants, and what is known about the drug and the study population. Guidance is available on reporting of safety data to appropriate authorities and on the content and timing of safety reports. See the following ICH Efficacy Guidelines guidances for industry and, for interventional clinical trials in particular, ICH E6(R2):

- **E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting** (March 1995)

- **E2B(R3) Electronic Transmission of Individual Case Safety Reports (ICSRs) Implementation Guide — Data Elements and Message Specification** (February 2014)

- **E2B(R3) Appendix I (B) to the ICH E2B(R3) ICSRs Implementation Guide — Backwards and Forwards Compatibility** (February 2014)
2. **Withdrawal Criteria (6.2.2)**

Clear criteria for stopping treatment or study procedures for a study participant while remaining in the study are necessary to ensure the protection of the participants but should also minimize loss of critical data.

3. **Data Monitoring Committee (6.2.3)**

An important component of safety monitoring in many clinical studies is the use of an independent data monitoring committee. This group monitors accumulating data while the study is being conducted to make recommendations on whether to continue, modify, or terminate a study.

During program planning, the need for an independent data monitoring committee to monitor safety data across studies in a development program should also be assessed. If a data monitoring committee is needed for either an individual study or across the development program, procedures governing its operation and, in particular the review of unblinded data in an interventional trial, while preserving study integrity (ICH E9) should be established before the study starts.

C. **Study Reporting (6.3)**

Clinical studies and their results should be adequately reported using formats appropriate for the type of study (interventional or observational studies) and information being reported. ICH E3 focuses particularly on the report format for interventional clinical trials, but the basic principles can be applied to other types of clinical studies (ICH guidance for industry *E3 Structure and Content of Clinical Study Reports—Questions and Answers (R1)* (January 2013). The design of the study report should be part of the quality by design process. The report should describe the
critical-to-quality factors in the study. The reporting of study results should be comprehensive, accurate, and timely.

Consideration should be given to providing a factual summary of the overall study results to study participants in an objective, balanced and nonpromotional manner, including relevant safety information and any limitations of the study. In addition, consideration could be given to providing individual participants with information about their study specific results (e.g., their treatment arm, test results). The information should be conveyed by someone involved in the health management of the participant (e.g., the clinical investigator). Participants should be informed about the information they will receive and when they will receive it at the time of providing informed consent.

The transparency of clinical research in drug development includes the registration of clinical studies, before they start, on publicly accessible and recognized databases, and the public posting of clinical study results. Adopting such practices for observational studies also promotes transparency. Making objective and unbiased information publicly available can benefit public health in general, as well as the indicated patient populations, through enhancing clinical research, reducing unnecessary clinical studies, and informing decisions in clinical practice.

VII. CONSIDERATIONS IN IDENTIFYING CRITICAL-TO-QUALITY FACTORS (7)

The identification of critical-to-quality factors should be supported by proactive, cross-functional discussions and decision-making at the time of study planning, as described in section III (3). Different factors will stand out as critical for different types of studies, following the concepts introduced in sections IV (4) through VI (6).

In designing a study, the following aspects should be considered, where applicable, to support the identification of critical-to-quality factors:

- Engagement of all relevant stakeholders, including patients, is considered during study planning and design.

- The prerequisite nonclinical studies, and where applicable, clinical studies, are complete and adequate to support the study being designed.

- The study objectives address relevant scientific questions appropriate for a given study’s role in the development program, taking into account the accumulated knowledge about the product.

- The clinical study design supports a meaningful comparison of the effects of the drug when compared to the chosen control group.

- Adequate measures are used to protect participants’ rights, safety, and welfare (informed consent process, Institutional Review Board/Ethics Committee review, investigator and clinical study site training, pseudonymization).
Contains Nonbinding Recommendations

- Information provided to the study participants should be clear and understandable.
- Competencies and training required for the study by sponsor and investigator staff, relevant to their role, should be identified.
- The feasibility of the study should be assessed to ensure the study is operationally viable.
- The number of participants included, the duration of the study, and the frequency of study visits are sufficient to support the study objective.
- The eligibility criteria should be reflective of the study objectives and be well documented in the clinical study protocol.
- The protocol specifies the collection of data needed to meet the study objectives, understand the benefit/risk of the drug, and monitor participant safety.
- The choice of response variables and the methods to assess them are well defined and support evaluation of the effects of the drug.
- Clinical study procedures include adequate measures to minimize bias (e.g., randomization, blinding).
- The statistical analysis plan is prespecified and defines the analysis methods appropriate for the endpoints and the populations of interest.
- Systems and processes are in place that support the study conduct to ensure the integrity of critical study data.
- The extent and nature of study monitoring are tailored to the specific study design and objectives and the need to ensure participants’ safety.
- The need for and appropriate role of a data monitoring committee is assessed.
- The reporting of the study results is planned, comprehensive, accurate, timely, and publicly accessible.

These considerations are not exhaustive and may not apply to all studies. Other aspects may need to be considered to identify the critical-to-quality factors for each individual study.
ANNEX: TYPES OF CLINICAL STUDIES

Drug development is ideally a logical, stepwise process in which information from early studies is used to support and plan later studies. The actual sequence of studies conducted in a particular drug development program, however, may reflect different dependencies and overlapping study types. Studies may also involve adaptive designs (which may bridge or combine different study types as listed below) or designs that are intended to investigate multiple drugs or multiple indications or both (e.g., studies conducted under a master protocol). In Table 1 below, types of clinical studies are categorized by objectives. Illustrative examples, not intended to be exhaustive or exclusive, are provided. Study objectives appearing under one type may also occur under another.

Table 1. Clinical Studies Categorized by Objectives

<table>
<thead>
<tr>
<th>Type of Study</th>
<th>Objectives of Study</th>
<th>Study Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human Pharmacology</td>
<td>• Assess tolerance and safety</td>
<td>• BA³/BE⁴ studies under fasted/fed conditions</td>
</tr>
<tr>
<td></td>
<td>• Define/describe clinical PK¹ and PD²</td>
<td>• Dose-tolerance studies</td>
</tr>
<tr>
<td></td>
<td>• Explore drug metabolism and drug interactions</td>
<td>• Single and multiple-rising dose PK and/or PD studies</td>
</tr>
<tr>
<td></td>
<td>• Evaluate activity, assess immunogenicity</td>
<td>• Drug-drug interaction studies</td>
</tr>
<tr>
<td></td>
<td>• Assess renal/hepatic tolerance</td>
<td>• QTc prolongation study</td>
</tr>
<tr>
<td></td>
<td>• Assess cardiac toxicity</td>
<td>• Human factor studies for drug delivery devices</td>
</tr>
<tr>
<td>Exploratory</td>
<td>• Explore use for the intended indication</td>
<td>• Randomized, controlled clinical trials of relatively short duration in well-defined narrow patient populations, using surrogate or pharmacological endpoints or clinical measures</td>
</tr>
<tr>
<td></td>
<td>• Estimate dose/dosing regimen for subsequent studies</td>
<td>• Dose-finding studies</td>
</tr>
<tr>
<td></td>
<td>• Explore dose-response/exposure-response relationship</td>
<td>• Biomarker exploration studies</td>
</tr>
<tr>
<td></td>
<td>• Provide basis for confirmatory study design (e.g., targeted population, clinical endpoints, patient-reported outcome measures, factors affecting treatment effects)</td>
<td>• Studies to validate patient-reported outcomes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Adaptive designs that may combine exploratory and confirmatory objectives</td>
</tr>
<tr>
<td>Type of Study</td>
<td>Objectives of Study</td>
<td>Study Examples</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------</td>
<td>----------------</td>
</tr>
</tbody>
</table>
| Confirmatory | • Demonstrate/confirm efficacy  
• Establish safety profile in larger, more representative patient populations  
• Provide an adequate basis for assessing the benefit/risk relationship to support licensing  
• Establish dose-response/exposure-response relationship  
• Establish safety profile and confirm efficacy in specific populations (e.g., pediatric, elderly) | • Randomized, controlled clinical trials to establish efficacy in larger, more representative patient populations  
• Dose-response studies  
• Clinical safety studies  
• Studies of mortality/morbidity outcomes  
• Studies in special populations  
• Studies that seek to demonstrate efficacy for multiple drugs in a single protocol |
| Postapproval | • Extend understanding of benefit/risk relationship in general or special populations and/or environments  
• Identify less common adverse reactions  
• Refine dosing recommendations | • Comparative effectiveness studies  
• Long-term follow-up studies  
• Studies of mortality/morbidity or other additional endpoints  
• Large, simple randomized trials  
• Pharmacoeconomic studies  
• Pharmacoepidemiology studies  
• Observational studies of the use of the drug in clinical practice  
• Disease or drug registries |

1PK - Pharmacokinetic  
2PD - Pharmacodynamic  
3BA - Bioavailability  
4BE – Bioequivalence